PE20080103A1 - AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-Tu - Google Patents
AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-TuInfo
- Publication number
- PE20080103A1 PE20080103A1 PE2007000664A PE2007000664A PE20080103A1 PE 20080103 A1 PE20080103 A1 PE 20080103A1 PE 2007000664 A PE2007000664 A PE 2007000664A PE 2007000664 A PE2007000664 A PE 2007000664A PE 20080103 A1 PE20080103 A1 PE 20080103A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- modulators
- compounds
- elongation factor
- aminotizoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS AMINOTIAZOLES DE FORMULA (I) DONDE A ES UN ENLACE, H, CH2, C(O), S(O)2, ENTRE OTROS; G ESTA AUSENTE O ES H, CICLOALQUILO, ARILO, ENTRE OTROS; J ES H, F, O-ALQUILO, CO2H, P(O)(OH)2, ENTRE OTROS; R1 ES H, C(ALQUILO)2-J O R4b; R2a ES H, ALQUILO, OH, OR4a, ENTRE OTROS; R2b ESTA AUSENTE O ES H, ALQUILO, ENTRE OTROS; R3 Y R12 SON CADA UNO H, HALOGENO, OR4b, ENTRE OTROS; R4a ES H O ALQUILO; R4b ES ALQUILO O (CH2-CH2-O-)n-R9, DONDE n ES DE 1 A 500; R9 ES H, ALQUILO O CH2CO2H; R5 ES H, ALQUILO O R4b. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (i), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL FACTOR DE ELONGACION EF-Tu SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES BACTERIANASREFERS TO AMINOTIAZOLES COMPOUNDS OF FORMULA (I) WHERE A IS A LINK, H, CH2, C (O), S (O) 2, AMONG OTHERS; G IS ABSENT OR IS H, CYCLOALKYL, ARYL, AMONG OTHERS; J IS H, F, O-ALKYL, CO2H, P (O) (OH) 2, AMONG OTHERS; R1 IS H, C (ALKYL) 2-J OR R4b; R2a IS H, ALKYL, OH, OR4a, AMONG OTHERS; R2b IS ABSENT OR IS H, RENT, AMONG OTHERS; R3 AND R12 ARE EACH H, HALOGEN, OR4b, AMONG OTHERS; R4a IS H OR ALKYL; R4b IS ALKYL O (CH2-CH2-O-) n-R9, WHERE n IS 1 TO 500; R9 IS H, ALKYL OR CH2CO2H; R5 IS H, ALKYL OR R4b. PREFERRED COMPOUNDS ARE THE COMPOUNDS OF FORMULA (i), AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE MODULATORS OF THE EF-Tu ELONGATION FACTOR, BEING USEFUL IN THE TREATMENT OF BACTERIAL INFECTIONS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80969306P | 2006-05-31 | 2006-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080103A1 true PE20080103A1 (en) | 2008-04-03 |
Family
ID=38645676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000664A PE20080103A1 (en) | 2006-05-31 | 2007-05-29 | AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-Tu |
| PE2012000528A PE20121011A1 (en) | 2006-05-31 | 2007-05-29 | AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-Tu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000528A PE20121011A1 (en) | 2006-05-31 | 2007-05-29 | AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-Tu |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7851439B2 (en) |
| EP (2) | EP2322536A3 (en) |
| JP (1) | JP5351014B2 (en) |
| KR (1) | KR101061658B1 (en) |
| CN (2) | CN101454337A (en) |
| AR (1) | AR060977A1 (en) |
| AU (1) | AU2007255025B2 (en) |
| BR (1) | BRPI0711885A2 (en) |
| CA (1) | CA2650133A1 (en) |
| CL (1) | CL2007001542A1 (en) |
| CR (1) | CR10430A (en) |
| DK (1) | DK2044101T3 (en) |
| EC (1) | ECSP088922A (en) |
| ES (1) | ES2441993T3 (en) |
| HR (1) | HRP20140055T1 (en) |
| IL (1) | IL194880A (en) |
| MA (1) | MA30485B1 (en) |
| MX (1) | MX2008015216A (en) |
| MY (1) | MY146920A (en) |
| NO (1) | NO20085032L (en) |
| NZ (1) | NZ572154A (en) |
| PE (2) | PE20080103A1 (en) |
| PL (1) | PL2044101T3 (en) |
| PT (1) | PT2044101E (en) |
| RU (1) | RU2450015C2 (en) |
| SI (1) | SI2044101T1 (en) |
| TN (1) | TNSN08496A1 (en) |
| TW (2) | TW201107337A (en) |
| UA (1) | UA95627C2 (en) |
| WO (1) | WO2007142986A2 (en) |
| ZA (1) | ZA200808449B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080103A1 (en) | 2006-05-31 | 2008-04-03 | Novartis Ag | AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-Tu |
| EP2097423B1 (en) * | 2006-12-20 | 2011-03-02 | Novartis AG | Aminothiazole macrocycles, their use as antibacterial compounds and processes for their production |
| WO2008148754A2 (en) | 2007-06-04 | 2008-12-11 | Novartis Ag | Macrocycles and their uses |
| AU2012261611B2 (en) * | 2007-12-12 | 2014-05-15 | Novartis Ag | Aminothiazoles and their uses |
| EA020205B1 (en) * | 2007-12-12 | 2014-09-30 | Новартис Аг | Aminothiazoles, pharmaceutical compositions based thereon and methods for treating bacterial infections |
| WO2014167371A1 (en) * | 2013-04-12 | 2014-10-16 | Naicons S.C.A.R.L. | Analogs of the antibiotic aminothiazole ge2270 |
| CN106366168B (en) * | 2016-08-26 | 2020-09-15 | 上海交通大学 | Preparation method of lanthiopeptide antibacterial peptide and its dehydroderivative |
| CN107243008B (en) * | 2017-04-13 | 2021-03-30 | 中国科学院广州生物医药与健康研究院 | New application of pyrazolo[1,5-a]pyridine compounds and a composition for treating Mycobacterium abscessus infection |
| CN113219078B (en) * | 2021-03-25 | 2022-12-16 | 广东产品质量监督检验研究院（国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室） | Rapid screening method for 17 organic antibacterial agents in household paper products |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202241A (en) | 1988-09-09 | 1993-04-13 | Gruppo Lepetit S.P.A. | Antibiotic GE 2270 |
| DE69016284T2 (en) | 1989-07-04 | 1995-05-24 | Lepetit Spa | Antibiotic GE 22270, factors A1, A2, A3 and H. |
| ATE121459T1 (en) | 1990-03-08 | 1995-05-15 | Lepetit Spa | ANTIBIOTICS GE 2270 FACTORS B1, B2, C1, D1, D2, E AND T. |
| IL100572A (en) | 1991-01-03 | 1997-01-10 | Lepetit Spa | Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them |
| DE69224497T2 (en) | 1991-08-30 | 1998-07-02 | Biosearch Italia Spa | Factor C2a of the antibiotic CE 2270 |
| US5882900A (en) * | 1992-09-10 | 1999-03-16 | Gruppo Lepetit S.P.A. | Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium |
| JPH08504782A (en) | 1992-12-22 | 1996-05-21 | グルポ・レペチツト・エス・ピー・エイ | Antibiotics GE37468A, B and C |
| AU3805295A (en) | 1994-11-08 | 1996-05-31 | Gruppo Lepetit S.P.A. | Microbial transformation process for obtaining antibiotic ge 2270 factor d2 |
| DE69600244T2 (en) | 1995-02-07 | 1998-10-01 | Biosearch Italia Spa | BASIC PROLINAMIDE DERIVATIVES OF GE2270 AND GE2270 LIGHT ANTIBIOTICS |
| AU693989B2 (en) | 1995-02-07 | 1998-07-09 | Vicuron Pharmaceuticals Inc. | Basic oxazoline-amide derivatives of GE 2270 and GE 2270-like antibiotics |
| JP2000505438A (en) * | 1996-02-14 | 2000-05-09 | バイオサーチ・イタリア・ソチエタ・ペル・アチオニ | Derivatives of antibiotic GE2270 factor C 2a, D 2 and E |
| JPH1059997A (en) * | 1996-08-22 | 1998-03-03 | Microbial Chem Res Found | Amitiamycinamide derivative |
| ATE509633T1 (en) | 2002-06-17 | 2011-06-15 | Naicons S C A R L | USE OF AN AMIDE DERIVATIVE OF GE 2270 FACTOR A3 FOR THE TREATMENT OF ACNE |
| CN101198318A (en) | 2004-09-22 | 2008-06-11 | 默克公司 | antibiotic compound |
| PE20080103A1 (en) | 2006-05-31 | 2008-04-03 | Novartis Ag | AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-Tu |
| EA020205B1 (en) * | 2007-12-12 | 2014-09-30 | Новартис Аг | Aminothiazoles, pharmaceutical compositions based thereon and methods for treating bacterial infections |
-
2007
- 2007-05-29 PE PE2007000664A patent/PE20080103A1/en not_active Application Discontinuation
- 2007-05-29 AR ARP070102300A patent/AR060977A1/en unknown
- 2007-05-29 PE PE2012000528A patent/PE20121011A1/en not_active Application Discontinuation
- 2007-05-30 WO PCT/US2007/012768 patent/WO2007142986A2/en not_active Ceased
- 2007-05-30 US US11/755,481 patent/US7851439B2/en active Active
- 2007-05-30 CN CNA2007800198364A patent/CN101454337A/en active Pending
- 2007-05-30 RU RU2008150785/04A patent/RU2450015C2/en not_active IP Right Cessation
- 2007-05-30 CA CA002650133A patent/CA2650133A1/en not_active Abandoned
- 2007-05-30 NZ NZ572154A patent/NZ572154A/en not_active IP Right Cessation
- 2007-05-30 JP JP2009513260A patent/JP5351014B2/en not_active Expired - Fee Related
- 2007-05-30 KR KR1020087029296A patent/KR101061658B1/en not_active Expired - Fee Related
- 2007-05-30 AU AU2007255025A patent/AU2007255025B2/en not_active Ceased
- 2007-05-30 HR HRP20140055TT patent/HRP20140055T1/en unknown
- 2007-05-30 PT PT77955029T patent/PT2044101E/en unknown
- 2007-05-30 MX MX2008015216A patent/MX2008015216A/en active IP Right Grant
- 2007-05-30 TW TW099141102A patent/TW201107337A/en unknown
- 2007-05-30 DK DK07795502.9T patent/DK2044101T3/en active
- 2007-05-30 EP EP10179066A patent/EP2322536A3/en not_active Withdrawn
- 2007-05-30 MY MYPI20084727A patent/MY146920A/en unknown
- 2007-05-30 SI SI200731371T patent/SI2044101T1/en unknown
- 2007-05-30 ES ES07795502.9T patent/ES2441993T3/en active Active
- 2007-05-30 UA UAA200811756A patent/UA95627C2/en unknown
- 2007-05-30 TW TW096119338A patent/TWI342310B/en not_active IP Right Cessation
- 2007-05-30 EP EP07795502.9A patent/EP2044101B1/en active Active
- 2007-05-30 PL PL07795502T patent/PL2044101T3/en unknown
- 2007-05-30 BR BRPI0711885-6A patent/BRPI0711885A2/en not_active Application Discontinuation
- 2007-05-30 CN CN201110384145.2A patent/CN102399260B/en not_active Expired - Fee Related
- 2007-05-30 CL CL200701542A patent/CL2007001542A1/en unknown
-
2008
- 2008-10-03 ZA ZA2008/08449A patent/ZA200808449B/en unknown
- 2008-10-23 IL IL194880A patent/IL194880A/en active IP Right Grant
- 2008-11-10 CR CR10430A patent/CR10430A/en unknown
- 2008-11-28 EC EC2008008922A patent/ECSP088922A/en unknown
- 2008-11-28 TN TNP2008000496A patent/TNSN08496A1/en unknown
- 2008-12-01 MA MA31428A patent/MA30485B1/en unknown
- 2008-12-02 NO NO20085032A patent/NO20085032L/en unknown
-
2010
- 2010-07-01 US US12/828,737 patent/US20100267757A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080103A1 (en) | AMINOTIZOLES AS MODULATORS OF THE ELONGATION FACTOR EF-Tu | |
| CO6300954A2 (en) | DERIVATIVES OF TIENOPIRIDINONES AS PROTEIN QUINASA ACTIVATORS ACTIVATED BY AMPK | |
| PE20091734A1 (en) | 2-IMINO-3-METHYLPYRROLOPYRIMIDINONE PHENYL-SUBSTITUTED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE | |
| PA8631901A1 (en) | 4-FENILLAMINO-QUINAZOLIN-6-IL-AMIDAS | |
| PE20110547A1 (en) | ISOINDOLINE COMPOUNDS WITH ANTI-CANCER ACTIVITY | |
| PE20081887A1 (en) | NEW ADENINE COMPOUND | |
| PE20090772A1 (en) | BENZIMIDAZOLE DERIVATIVES | |
| PE20120691A1 (en) | DERIVATIVES OF N1-SULFONYL-5-FLUOROPYRIMIDINONE | |
| PE20090648A1 (en) | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | |
| SV2006002110A (en) | THERAPEUTIC COMPOUNDS REF. PC32293A | |
| PE20091237A1 (en) | PYRROLIDINE DERIVATIVES AS MODULATORS OF SERINE PROTEASES | |
| PE20110344A1 (en) | ETHANODIAMIDE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
| PE20080263A1 (en) | PIRROLO-PYRIMIDINE COMPOUNDS AND THEIR USES | |
| PE20080361A1 (en) | PURINE-DERIVED COMPOUNDS AS ADENOSINE A2A RECEPTOR ACTIVATORS | |
| PE20081800A1 (en) | NEW DERIVATIVES OF 3 - ([1,2,4] TRIAZOLO [4,3-a] PYRIDIN-7-IL) BENZAMIDE | |
| PE20080070A1 (en) | INDOLOBENZAZEPINE DERIVATIVES FUSED TO CYCLOPROPYL AS INHIBITORS OF THE POLYMERASE NS5B OF THE HEPATITIS C VIRUS | |
| PE20120632A1 (en) | BACE INHIBITORS | |
| UY32462A (en) | NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT | |
| PE20090816A1 (en) | PYRROLOPYRIMIDINONE DERIVATIVES AS BINDING AGENTS OF P2X3 RECEPTORS | |
| PE20090057A1 (en) | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | |
| CL2009000619A1 (en) | Carbazole derived compounds, hsp90 protein inhibitors; procedure for preparing the compounds; intermediate compounds, pharmaceutical composition comprising one of the compounds; and the use of the compounds in the treatment of cancer. | |
| UY28005A1 (en) | INDOL -3-CARBOXAMIDS AS GLUCOQUINASE ACTIVATORS (GK) | |
| ECSP10010654A (en) | TIENOPIRIDON DERIVATIVES AS AMP ACTIVATED KINASE PROTEIN ACTIVATORS (AMPK) | |
| PE20071311A1 (en) | 8-AZABICYCLE COMPOUNDS [3.2.1] OCTANE AS ANTAGONISTS OF THE OPIOID RECEPTOR MU | |
| GT200600517A (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |